Physician profile
Marly Maxime
NPI 1700262789
$1,383.43
in general payments reported to CMS, 2019-2025
11 companies · $431 in 2025
The $431 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.19 · 2023: $348 · 2024: $563 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $586.60 | 2022-2025 | Ztlido |
| Nevro Corp. | $218.26 | 2024 | Senza |
| Valinor Pharma, LLC | $192.86 | 2023-2025 | Movantik |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.06 | 2023-2025 | Relistor |
| Forte Bio-Pharma LLC | $66.87 | 2023-2024 | Prolate, Nalocet |
| Ibsa Pharma INC. | $56.39 | 2023-2024 | Tirosint, Licart, Tirosint |
| Averitas Pharma INC. | $47.52 | 2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $41.47 | 2025 | Xtampza |
| Spinal Simplicity, LLC | $22.37 | 2023 | Ha Minuteman G3-R |
| Smith+Nephew, INC. | $18.10 | 2025 | Grafix Pl, Stravix |
| Abbvie INC. | $15.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marly Maxime listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.